GSK's Shingrix blows past sales projections, pushing 2018 estimates to $600M

GlaxoSmithKline's Shingrix carried high expectations, but it turns out that those ambitious projections weren't high enough. In the first quarter, the shingles vaccine generated £110 million, nearly triple analyst estimates of £40 million. And the revenue couldn't come at a better time for GSK.